Cipla to pay Rs 166 crore for majority stake in Ugandan Quality Chemicals

Published On 2015-07-26 12:41 GMT   |   Update On 2015-07-26 12:41 GMT

New Delhi, Jul 24 : Drug major Cipla has re-negotiated payment terms for acquiring majority stake in Uganda's Quality Chemicals and now decided to pay USD 26 million (around Rs 166 crore) upfront to the shareholders of the African firm.Cipla (EU), a wholly-owned subsidiary of the company, has re-negotiated the terms of the agreement and have entered into an amendment for upfront payment of...

Login or Register to read the full article
New Delhi, Jul 24 : Drug major Cipla has re-negotiated payment terms for acquiring majority stake in Uganda's Quality Chemicals and now decided to pay USD 26 million (around Rs 166 crore) upfront to the shareholders of the African firm.

Cipla (EU), a wholly-owned subsidiary of the company, has re-negotiated the terms of the agreement and have entered into an amendment for upfront payment of the consideration amount instead of payment in tranches over a period of 5 years, the Mumbai-based company said in a statement.

"Accordingly, the revised consideration is around USD 26 million (USD 25,995,730) payable upfront upon completion of conditions precedent," it added.

In May, Cipla had inked a pact with Quality Chemicals Ltd (QCL) to acquire majority stake in it for a total consideration of over USD 30 million (around Rs 190 crore).

Cipla (EU) had entered into a definitive agreement to acquire a 51 per cent stake inQuality Chemicals Ltd (QCL) from its existing shareholders.

As per the agreement inked earlier, the cash consideration for 51 per cent stake was payable in tranches with around USD 8 million payable upfront on completion and 5 equal installments of USD 4.41 million payable at annual intervals thereafter.

QCL was incorporated in the year 1997 and is engaged in the business of import and distribution of pharmaceutical and consumer products.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News